Meda Pharmaceuticals Inc. provides pharmaceutical products Europe, the United States, and internationally. The company’s portfolio primarily focuses on respiratory, allergy, central nervous system, gastroenterology, musculoskeletal, rheumatology, erectile dysfunction, and women's health products. Its products include inhalation and topical aerosols, tablets, creams, nasal sprays, flavored soluble powders, capsules, rectal and hemorrhoidal foams, gels, oral concentrates, injections, oral and extended-release tablets, chewable melt tablets, softgels, rectal suspensions, and ophthalmic solutions. Meda Pharmaceuticals Inc. was formerly known as MedPointe, Inc. and changed its name to Meda Pharma...
265 Davidson Avenue
Somerset, NJ 08873-4120
Founded in 2001
Meda To Reportedly Sell Meda Pharmaceuticals
Aug 28 15
Meda AB (OM:MEDA A) intends to sell Meda Pharmaceuticals Inc. Meda is exploring options to sell Meda Pharmaceuticals, which could be worth about $1 billion, Bloomberg reported, citing people familiar with the matter. Meda plans to use the funds to reduce debt and seek other acquisitions, Bloomberg said. Rothschild is advising Meda on the sale process. Reuters added that Meda could not immediately be reached for comment outside regular business hours.
Meda Inc. (US) Announces Executive Chagnes
Oct 2 14
Ton van't Hullenaar, Executive Vice President will additionally take on the responsibility for Meda Inc. (US). Maria Carell Executive Vice President North America /Australia, and President Meda Inc. (US) resigns from her positions to pursue other opportunities outside of the company. Ton will assume the responsibility as country manager US until a successor has been appointed.